ATE501256T1 - Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung - Google Patents

Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung

Info

Publication number
ATE501256T1
ATE501256T1 AT03770858T AT03770858T ATE501256T1 AT E501256 T1 ATE501256 T1 AT E501256T1 AT 03770858 T AT03770858 T AT 03770858T AT 03770858 T AT03770858 T AT 03770858T AT E501256 T1 ATE501256 T1 AT E501256T1
Authority
AT
Austria
Prior art keywords
seq
amino acid
recombinant protein
protein
same activity
Prior art date
Application number
AT03770858T
Other languages
German (de)
English (en)
Inventor
Bing Zhu
Original Assignee
Beijing Sunbio Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Sunbio Biotech Co Ltd filed Critical Beijing Sunbio Biotech Co Ltd
Application granted granted Critical
Publication of ATE501256T1 publication Critical patent/ATE501256T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03770858T 2003-11-03 2003-11-03 Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung ATE501256T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2003/000928 WO2005042744A1 (en) 2003-11-03 2003-11-03 A recombinant protein with cancer suppression action, its encoding gene and use

Publications (1)

Publication Number Publication Date
ATE501256T1 true ATE501256T1 (de) 2011-03-15

Family

ID=34529378

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03770858T ATE501256T1 (de) 2003-11-03 2003-11-03 Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung

Country Status (11)

Country Link
US (1) US7666989B2 (enExample)
EP (1) EP1688498B1 (enExample)
JP (1) JP4688678B2 (enExample)
CN (1) CN100549175C (enExample)
AT (1) ATE501256T1 (enExample)
AU (1) AU2003280921B2 (enExample)
BR (1) BRPI0318594B8 (enExample)
CA (1) CA2544473C (enExample)
DE (1) DE60336353D1 (enExample)
NZ (1) NZ547274A (enExample)
WO (1) WO2005042744A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063221A1 (ja) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited メタスチン誘導体およびその用途
PE20091567A1 (es) 2004-06-25 2009-11-03 Takeda Pharmaceutical Derivados de metastina en el tratamiento del cancer
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI404726B (zh) 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
US20110118172A1 (en) * 2008-04-24 2011-05-19 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
HRP20150664T1 (hr) 2010-12-03 2015-07-31 Adamed Sp. Z O.O. Antikancerogeni fuzijski protein
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
PL394618A1 (pl) 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
WO2013037090A1 (zh) 2011-09-16 2013-03-21 北京沙东生物技术有限公司 包含trail/apo2l环化变构体的融合蛋白及其编码基因与应用
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
PL223487B1 (pl) 2011-12-28 2016-10-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
EP1666591B1 (en) * 1995-06-29 2011-03-23 Immunex Corporation Cytokine that induces apoptosis
KR20010019100A (ko) * 1999-08-25 2001-03-15 황규언 인간 유래 세포소멸인자 trail의 결정화에 의한 3차원 구조
US6900185B1 (en) * 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
KR100436089B1 (ko) * 2000-07-06 2004-06-14 설대우 분비성 재조합 트라이머형의 트레일 단백질 생산을 위한 디엔에이 카세트, 테트라사이클린/독시사이클린-유도성아데노-관련 바이러스 벡터, 이 둘의 조합, 및 이들을이용한 유전자 치료
CN1205335C (zh) * 2001-11-30 2005-06-08 中国人民解放军第二军医大学 肿瘤凋亡诱导配体基因、基因表达蛋白及其制备方法

Also Published As

Publication number Publication date
CA2544473C (en) 2013-08-13
EP1688498B1 (en) 2011-03-09
WO2005042744A1 (en) 2005-05-12
NZ547274A (en) 2009-02-28
BRPI0318594B8 (pt) 2021-05-25
US20080280821A1 (en) 2008-11-13
CA2544473A1 (en) 2005-05-12
CN100549175C (zh) 2009-10-14
HK1089788A1 (zh) 2006-12-08
CN1860229A (zh) 2006-11-08
BR0318594A (pt) 2006-10-17
JP4688678B2 (ja) 2011-05-25
BRPI0318594B1 (pt) 2017-12-26
DE60336353D1 (de) 2011-04-21
US7666989B2 (en) 2010-02-23
JP2007536891A (ja) 2007-12-20
EP1688498A1 (en) 2006-08-09
AU2003280921B2 (en) 2007-09-13
AU2003280921A1 (en) 2005-05-19
EP1688498A4 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
WO2010135491A3 (en) Fibroblast growth factor mutants having improved functional half-life and methods of their use
ATE501256T1 (de) Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
ATE417595T1 (de) Keratin-bindende polypeptide
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
ATE476507T1 (de) Transkriptionsfaktor aus arabidopis thaliana sowie codierendes gen und verwendung davon
DE60138558D1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
JP2004505640A5 (enExample)
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
JP2007536891A5 (enExample)
RU2006119452A (ru) Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение
JP2003334088A5 (enExample)
CA2422295A1 (en) A gene of aluminum-activated malate transporter of a plant and a protein encoded by the gene
SI1673391T1 (sl) Modificirana cDNA za visoke ekspresijske nivoje faktorja VIII in njegovih derivatov
WO2002034882A3 (en) Genes regulating programmed cell death
GB2441941A (en) An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide
DE50211988D1 (de) Modifizierte tridegine, ihre herstellung und verwendung als transglutaminase-inhibitoren
CA2498651A1 (en) Nucleoside triphosphate diphosphohydrolase and uses thereof
WO2009069546A1 (ja) 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
ATE423200T1 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon
ATE414155T1 (de) Moraxella (branhamella) catarrhalis polypeptide
ATE286535T1 (de) Regulatorisches protein pke 83 aus humanen keratinozyten
RU2008130819A (ru) Способ продукции рекомбинантной стафилокиназы при регулировании уровня кислорода
DE602007009797D1 (de) Antitumorheilmittel, Medikament, Zusammensetzung und Verwendung davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties